Idelalisib, a specific inhibitor for p110δ, is the first PI3KI approved for the treatment of relapsed chronic lymphocytic leukemia in combination with CD-20 antibody rituximab [37]. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.